Giotrif (afatinib dimaleate): Reviews and patient testimonials

/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Medication indications

Giotrif 20 mg/30 mg/40 mg/50 mg film-coated tablets

GIOTRIF as monotherapy is indicated for the treatment of

• Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s);

• locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.


Route of administration: Oral
Molecule: afatinib dimaleate

Patients' opinions on Giotrif

In brief

General satisfaction level: 1.00/10 Learn more

Treatment's effectiveness: 1.00/10 Learn more

Ease of use: 1.00/10 Learn more

Adherence to prescription: 1.00/10 Learn more

Detected side effects: 1.00/10 Learn more

Improvement in the quality of life: Be the first to evaluate

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community


avatar
SandraT
on 05/02/2020

I’ve only been on this drug 6 weeks and my tumour is shrunk in half . I’m really trying to stay positive and hope it continues to shrink and give me lots more time with my family

Your message

Members using this Giotrif

Conditions related to this medication

Fact sheet

Lung cancer

See the fact sheet